<DOC doc_id="AFP_ENG_20041001.0380" type="story">
<HEADLINE>
European Medicines Agency to review drugs in same class as Vioxx
</HEADLINE>
<DATELINE>
LONDON, Oct 1 (AFP)
</DATELINE>
<TEXT>
<S s_id="0">
European Medicines Agency to review drugs in same class as Vioxx
</S>
<S s_id="1">
The European Medicines Agency is to review all drugs in the same class as Vioxx after US pharmaceutical giant Merck withdrew the arthritis drug, a spokesman for the agency said Friday.
</S>
<S s_id="2">
Merck announced a global withdrawal Thursday of Vioxx, a blockbuster arthritis drug, after a study showed it increased the risk of strokes and heart attacks.
</S>
<S s_id="3">
"We are going to see whether there is a class effect," a spokesman for the London-based agency said.
</S>
<S s_id="4">
The US Food and Drug Administration also has said it would study the effects of other drugs in the same class as the withdrawn drug.
</S>
<S s_id="5">
Vioxx, which is scientifically known as rofecoxib, has been marketed in more than 80 countries and produced sales of 2.5 billion dollars in 2003.
</S>
<S s_id="6">
The European Medicines Agency carried out a review of the drug class which includes Vioxx -- known as COX-2 inhibitors -- at the request of French authorities, but concluded in November 2003 that the products did not need to be withdrawn from the market.
</S>
</TEXT>
</DOC>
